This study was conducted to examine the role of tumor-redirected MHC class I-restricted CD4+ in comparison to tumor-redirected CD8+ T cells against a STEAP1-derived HLA-A*02:01 restricted peptide. This evidence concerns the gene CD8A and neoplasm.